000126054 001__ 126054
000126054 005__ 20240228140805.0
000126054 0247_ $$2doi$$a10.1007/s00428-015-1736-5
000126054 0247_ $$2pmid$$apmid:25697539
000126054 0247_ $$2ISSN$$a0042-6423
000126054 0247_ $$2ISSN$$a0945-6317
000126054 0247_ $$2ISSN$$a1432-2307
000126054 037__ $$aDKFZ-2017-02169
000126054 041__ $$aeng
000126054 082__ $$a610
000126054 1001_ $$aAntonelli, Manila$$b0
000126054 245__ $$aLong-term survival in a case of ETANTR with histological features of neuronal maturation after therapy.
000126054 260__ $$aBerlin$$bSpringer$$c2015
000126054 3367_ $$2DRIVER$$aarticle
000126054 3367_ $$2DataCite$$aOutput Types/Journal article
000126054 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508397844_7062
000126054 3367_ $$2BibTeX$$aARTICLE
000126054 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126054 3367_ $$00$$2EndNote$$aJournal Article
000126054 520__ $$aEmbryonal tumor with abundant neuropil and true rosettes (ETANTR) is a rare subtype of primitive neuroectodermal tumors and one of the most aggressive brain tumors in children. The neoplasm harbors a specific genetic alteration, amplification of the miRNA cluster C19MC at 19q13.42. We report a case of a 21-month-old boy with a mass in the left fronto-opercular region. The lesion was partially resected and pathology examination revealed an ETANTR with immunoreativity for LIN28A protein and amplification of the C19MC locus. The child received the PNET infant indications followed by high-dose thiotepa which resulted in a significant reduction of the mass. Subsequently, a second operation was carried out and the residual mass removed. Histology at this time showed a low-grade lesion composed of neuronal cells ranging from neurocytes to ganglion cells embedded in abundant neuropil with no immature embryonal component and multilayered rosettes. In addition to these features, a decrease in the number of nuclei with amplification of the C19MC locus was also observed. Thirty-one months after the second operation, the patient is alive and well. Such long-term survival could be explained by neuronal maturation induced by therapy associated with reduction of neoplastic cells with amplification of C19MC locus. This case suggests that the induction of differentiation may represent an optimal treatment strategy for very aggressive malignancies as ETANTR.
000126054 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000126054 588__ $$aDataset connected to CrossRef, PubMed,
000126054 650_7 $$2NLM Chemicals$$aMicroRNAs
000126054 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b1$$udkfz
000126054 7001_ $$aMastronuzzi, Angela$$b2
000126054 7001_ $$aDiomedi Camassei, Francesca$$b3
000126054 7001_ $$aCarai, Andrea$$b4
000126054 7001_ $$aColafati, Giovanna S$$b5
000126054 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b6$$udkfz
000126054 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b7$$udkfz
000126054 7001_ $$aGiangaspero, Felice$$b8
000126054 773__ $$0PERI:(DE-600)1463276-7$$a10.1007/s00428-015-1736-5$$gVol. 466, no. 5, p. 603 - 607$$n5$$p603 - 607$$tVirchows Archiv$$v466$$x1432-2307$$y2015
000126054 909CO $$ooai:inrepo02.dkfz.de:126054$$pVDB
000126054 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000126054 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000126054 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000126054 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000126054 9141_ $$y2015
000126054 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000126054 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVIRCHOWS ARCH : 2015
000126054 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126054 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126054 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126054 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126054 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126054 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126054 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126054 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000126054 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126054 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126054 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000126054 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x1
000126054 980__ $$ajournal
000126054 980__ $$aVDB
000126054 980__ $$aI:(DE-He78)G380-20160331
000126054 980__ $$aI:(DE-He78)B062-20160331
000126054 980__ $$aUNRESTRICTED